INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 319 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.64 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $94,860 | -22.5% | 3,000 | 0.0% | 0.00% | -33.3% |
| Q2 2023 | $122,340 | +118.8% | 3,000 | +100.0% | 0.00% | +200.0% |
| Q1 2023 | $55,905 | +7.5% | 1,500 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $52,000 | -38.1% | 1,500 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $84,000 | -16.8% | 1,500 | -23.1% | 0.00% | -33.3% |
| Q2 2022 | $101,000 | -28.9% | 1,950 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $142,000 | -19.8% | 1,950 | +30.0% | 0.00% | -25.0% |
| Q4 2021 | $177,000 | -11.9% | 1,500 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $201,000 | -58.6% | 1,500 | -50.0% | 0.00% | -63.6% |
| Q2 2021 | $486,000 | -97.9% | 3,000 | -98.9% | 0.01% | -97.8% |
| Q1 2021 | $22,914,000 | +6928.8% | 285,520 | +4658.7% | 0.50% | +6212.5% |
| Q4 2020 | $326,000 | +63.8% | 6,000 | -40.0% | 0.01% | +33.3% |
| Q3 2020 | $199,000 | -5.2% | 10,000 | 0.0% | 0.01% | -14.3% |
| Q2 2020 | $210,000 | +72.1% | 10,000 | 0.0% | 0.01% | +40.0% |
| Q1 2020 | $122,000 | -17.0% | 10,000 | 0.0% | 0.01% | -16.7% |
| Q4 2019 | $147,000 | +37.4% | 10,000 | +25.0% | 0.01% | +50.0% |
| Q3 2019 | $107,000 | -18.3% | 8,000 | 0.0% | 0.00% | -20.0% |
| Q2 2019 | $131,000 | -4.4% | 8,000 | 0.0% | 0.01% | -16.7% |
| Q1 2019 | $137,000 | +42.7% | 8,000 | +14.3% | 0.01% | +50.0% |
| Q4 2018 | $96,000 | -52.0% | 7,000 | 0.0% | 0.00% | -42.9% |
| Q3 2018 | $200,000 | +4.2% | 7,000 | 0.0% | 0.01% | 0.0% |
| Q2 2018 | $192,000 | +29.7% | 7,000 | 0.0% | 0.01% | +40.0% |
| Q1 2018 | $148,000 | -45.2% | 7,000 | -50.0% | 0.01% | 0.0% |
| Q4 2017 | $270,000 | +55.2% | 14,000 | +100.0% | 0.01% | -16.7% |
| Q3 2017 | $174,000 | +141.7% | 7,000 | +55.6% | 0.01% | +200.0% |
| Q2 2017 | $72,000 | +14.3% | 4,500 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $63,000 | +61.5% | 4,500 | +50.0% | 0.00% | +100.0% |
| Q4 2016 | $39,000 | -23.5% | 3,000 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $51,000 | -20.3% | 3,000 | 0.0% | 0.00% | -50.0% |
| Q2 2016 | $64,000 | – | 3,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 572,950 | $19,990,226 | 5.79% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $39,952,225 | 5.34% |
| MPM BioImpact LLC | 455,238 | $15,883,254 | 4.12% |
| ARK Investment Management | 9,420,782 | $328,691,084 | 2.85% |
| Atlas Venture Associates IX, LLC | 10,000 | $348,900 | 1.74% |
| Ghisallo Capital Management LLC | 250,000 | $8,722,500 | 1.55% |
| Nikko Asset Management Americas, Inc. | 2,976,002 | $103,743,430 | 1.49% |
| Prosight Management, LP | 72,116 | $2,516,127 | 1.37% |
| Rokos Capital Management LLP | 826,063 | $28,391,785 | 1.24% |
| Elmwood Wealth Management, Inc. | 67,899 | $2,368,996 | 1.18% |